Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $661.8552W HIGH $1,072.75
Volume
225.89 K
Value Traded
218.31 M
Short % Float
2.25%
Days to Cover
3.4
-0.23%Week
+13.44%1 Month
-2.81%3 Month
+23.68%6 Month
+197.06%5 Year
+4,405.36%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
60.37 B
EPS (TTM)
21.10
P/E Ratio
45.51
Ent. Value
45.93 B
Total Shares
62.89 M
Float Shares
62.76 M
Insiders
0.19%
Institutions
45.81%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ARGX Catalyst Timeline
Dated clinical, regulatory and corporate events for argenx SE
Catalyst Timeline
Dated clinical, regulatory & corporate events for argenx SE
782Total events
22Upcoming
253Tier-1 (high impact)
2015 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Late-BreakerEfgartigimodApprovedPresentation
ALKIVIA data featured in late-breaking oral presentation at ACR Convergence 2026
autoimmune myositissource ↗
▲AcquisitionCorporate
argenx signs definitive agreement to acquire Unnatural Products for up to ~$1.15B
▲AcquiredCorporate
argenx to acquire Unnatural Products for up to ~$1.15B ($550M upfront plus CVRs)
▲Secondary Endpoint DataEfgartigimodApprovedClinical Data
IMNM subtype showed 14.8-point greater TIS improvement vs placebo at Week 52
immune-mediated necrotizing myopathy (IMNM)source ↗
●Subgroup AnalysisEfgartigimodApprovedClinical Data
DM subgroup showed 14.5-point greater TIS improvement vs placebo at Week 52, not statistically significant (p=0.1093)
dermatomyositis (DM)source ↗
●Safety Data UpdateEfgartigimodApprovedClinical Data
Efgartigimod generally well tolerated in ALKIVIA, consistent with known safety profile
autoimmune myositissource ↗
▲Primary Endpoint MetEfgartigimodApprovedClinical Data
ALKIVIA met primary endpoint in combined IMNM and DM population
autoimmune myositis (combined IMNM and DM)source ↗
●Quarterly UpdateCorporate
argenx reports third quarter 2026 financial results and business update
▲Primary Endpoint MetFB102Clinical Data
FB102 met primary endpoint of change in Vh:Cd ratio at day 78 (p=0.0176)
celiac diseasesource ↗
▲Topline ReadoutFB102Clinical Data
Positive topline results from Phase 2 study of FB102 in celiac disease
celiac diseasesource ↗
▼Trial Stopped FutilityEfgartigimodApprovedTrial
argenx discontinues Phase 3 UNITY study of efgartigimod SC in Sjögren's disease for futility
Sjögren's diseasesource ↗
▼Interim AnalysisEfgartigimodApprovedTrial
Interim analysis of Phase 3 UNITY study led to IDMC futility recommendation
Sjögren's diseasesource ↗
▼Trial DiscontinuedEfgartigimodApprovedTrial
Phase 3 UNITY study of efgartigimod SC in Sjögren's disease discontinued
Sjögren's diseasesource ↗
▲Oral PresentationEfgartigimodApprovedPresentation
Efgartigimod in AChR Antibody Negative gMG: Efficacy and Safety Results from ADAPT SERON
Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravissource ↗
▲Poster PresentationEmpasiprubartPresentation
Phase 2 ARDA+ results showing sustained clinical benefit of empasiprubart in MMN presented at AANEM
Multifocal Motor Neuropathy (MMN)source ↗
▲Poster PresentationEfgartigimodApprovedPresentation
Longitudinal analysis of response as first-line treatment with VYVGART Hytrulo in CIDP presented at AANEM
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)source ↗
▲Poster PresentationARGX-119Presentation
Phase 1b digital gait outcomes of adimanebart in DOK7-CMS presented at AANEM
DOK7-Congenital Myasthenic Syndromes (CMS)source ↗
●Poster PresentationPresentation
Understanding the Patient Journey in MMN: Descriptive Insights From the iMMersioN Study
Multifocal Motor Neuropathysource ↗
▲Oral PresentationEfgartigimodApprovedPresentation
Sustained Efficacy in anti-AChR antibody-negative MG (MGFA Oral #72)
Generalized Myasthenia Gravis (anti-AChR antibody-negative)source ↗
▲Poster PresentationEfgartigimodApprovedPresentation
Early Grip Strength Improvement in CIDP (AANEM Poster #343)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)source ↗
▲Oral PresentationEfgartigimodApprovedPresentation
One-year ADAPT SERON results in anti-AChR antibody-negative gMG presented at MGFA
Generalized Myasthenia Gravis (anti-AChR antibody-negative)source ↗
●Poster PresentationEfgartigimodApprovedPresentation
Real-world evidence on disease burden in AChR-Ab-negative vs positive gMG from MyaReg presented at MGFA
Generalized Myasthenia Gravissource ↗
●Corporate ApprovalCorporate
argenx shareholders approve resolutions at Extraordinary General Meeting
●Management ChangeCorporate
Thomas M. Brakel and Khurem Farooq appointed as Non-Executive Directors
▲Primary Endpoint MetClinical Data
ALKIVIA met primary endpoint of mean TIS at Week 52
autoimmune myositissource ↗
▲Topline ReadoutClinical Data
Positive topline results from Phase 3 ALKIVIA trial of efgartigimod in autoimmune myositis
autoimmune myositissource ↗
▲Quarterly UpdateCorporate
Half Year 2026 Financial Results and Second Quarter Business Update
◆Topline ReadoutEfgartigimodApprovedClinical Data
Topline results from registrational ALKIVIA study (myositis) expected
myositissource ↗
▲Timing GuidanceFB102Presentation
FB102 advancing to Phase 3 in celiac disease based on positive Phase 2 results
celiac diseasesource ↗
▲FDA Filing AcceptedEfgartigimodApprovedRegulatory Filing
sBLA for VYVGART and VYVGART Hytrulo in pediatric gMG accepted for priority review by FDA
pediatric gMGsource ↗
▲Priority ReviewEfgartigimodApprovedRegulatory Filing
FDA granted priority review to sBLA for VYVGART and VYVGART Hytrulo in pediatric gMG
pediatric gMGsource ↗
●sBLA SubmissionEfgartigimodApprovedRegulatory Filing
sBLA submitted to FDA for VYVGART in ocular myasthenia gravis
ocular myasthenia gravis (oMG)source ↗
●R&D DayPresentation
R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis Webinar
▲Poster PresentationEfgartigimodApprovedPresentation
Poster presentation of cross-indication safety analysis at EULAR 2026
multiple autoimmune diseasessource ↗
▲Poster PresentationEfgartigimodApprovedPresentation
Poster presentation of ALKIVIA+ long-term safety and efficacy results at EULAR 2026
myositissource ↗
▲Oral PresentationEfgartigimodApprovedPresentation
Oral presentation of RHO+ long-term efficacy and safety results at EULAR 2026
Sjogren's diseasesource ↗
◆Additional DataEmpasiprubartClinical Data
52-week efficacy analysis for VARVARA (DGF) expected mid-year 2026
delayed graft function (DGF)source ↗
◆Oral PresentationPresentation
argenx CEO to present at BofA Securities 2026 Health Care Conference
◆PDUFA DateEfgartigimodApprovedRegulatory Filing
PDUFA target action date for seronegative gMG
anti-acetylcholine receptor antibody negative (AChR-Ab-) generalized myasthenia gravis (gMG)source ↗
▲Supplemental ApprovalEfgartigimodApprovedFDA Decision
FDA approved label expansion for VYVGART and VYVGART Hytrulo for all serotypes of adult gMG
generalized myasthenia gravissource ↗
▲Primary Endpoint MetEfgartigimodApprovedClinical Data
ADAPT SERON met primary endpoint (p=0.0068) showing MG-ADL improvement at week 4
generalized myasthenia gravis (seronegative)source ↗
▲Topline ReadoutClinical Data
Positive top-line results from ADAPT OCULUS study of VYVGART Hytrulo in ocular MG
ocular myasthenia gravissource ↗
Past FDA Catalysts and PDUFA Decisions
How ARGX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-11 | VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc; efgartigimod PH20 SC) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
9
Drugs Scored
rNPV / MCap
Top Drug
Top 13%
Large Pharma(rank 90 of 687)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (20-F and 6-K), to Jun 2026; product lines: last four quarters to Jun 2026 (20-F and 6-K))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| VYVGART |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Empasiprubart BiologicsNCT06920004 | Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | RECRUITING | 378 | Sep 1, 2030 | ||||||
| Empasiprubart BiologicsNCT06742190 | Multifocal Motor Neuropathy (MMN) | Phase 3 | ACTIVE NOT_RECRUITING | 214 | Dec 1, 2029 | ||||||
| Empasiprubart BiologicsNCT06284954 | Dermatomyositis | Phase 2 | ACTIVE NOT_RECRUITING | 3 | Nov 1, 2026 | ||||||
| ARGX-117 BiologicsNCT05907096 | Delayed Graft Function | Phase 2 | ACTIVE NOT_RECRUITING | 103 | May 1, 2030 | ||||||
| ARGX-117 BiologicsNCT05405361 | Multifocal Motor Neuropathy | Phase 2 | ACTIVE NOT_RECRUITING | 105 | Sep 30, 2029 | ||||||
| Empasiprubart BiologicsNCT07821762 | Guillain-Barré Syndrome (GBS) | Phase 2 | NOT YET_RECRUITING | 63 | Mar 1, 2029 | ||||||
| Empasiprubart BiologicsNCT07673627 | AChR-Ab Seropositive Generalized Myasthenia Gravis | Phase 2 | RECRUITING | 40 | Apr 1, 2028 | ||||||
| ARGX-121 BiologicsNCT07773727 | Immunoglobulin A Nephropathy (IgAN) | Phase 2 | RECRUITING | 120 | Feb 18, 2030 | ||||||
| Efgartigimod BiologicsNCT07194850 | Immune Thrombocytopenia (ITP) | Phase 2/3 | RECRUITING | 24 | Oct 1, 2030 | ||||||
| Efgartigimod PH20 SC BiologicsNCT04812925 | Primary Immune Thrombocytopenia | Phase 3 | ACTIVE NOT_RECRUITING | 380 | Oct 1, 2027 | ||||||
| Efgartigimod PH20 SC BiologicsNCT06684847 | Primary Sjogrens Disease | Phase 3 | ACTIVE NOT_RECRUITING | 631 | Jul 1, 2028 | ||||||
| Efgartigimod PH20 SC BiologicsNCT07570316 | Graves Disease | Phase 3 | RECRUITING | 460 | May 1, 2030 | ||||||
| Efgartigimod PH20 SC BiologicsNCT05979441 | Myositis | Phase 3 | ENROLLING BY_INVITATION | 240 | Sep 1, 2028 | ||||||
| Efgartigimod BiologicsMarketedNCT06298552 | Generalized Myasthenia Gravis | Approved | ACTIVE NOT_RECRUITING | 215 | Jun 1, 2028 | ||||||
| Efgartigimod PH20 SC Small MoleculesNCT06558279 | Myasthenia Gravis, Ocular | Phase 3 | ACTIVE NOT_RECRUITING | 141 | Dec 1, 2027 | ||||||
| Efgartigimod Small MoleculesMarketedNCT06765161 | Myasthaenia Gravis | Approved | RECRUITING | 30 | Jan 6, 2027 | ||||||
| Efgartigimod PH20 SC BiologicsNCT07583641 | Autoimmune Encephalitis (AE) | Phase 2 | NOT YET_RECRUITING | 170 | Jul 30, 2030 | ||||||
| Efgartigimod PH20 SC BiologicsNCT07760818 | Sjogrens Disease | Phase 2 | NOT YET_RECRUITING | 75 | Jul 28, 2029 | ||||||
| Efgartigimod PH20 SC Small MoleculesNCT06503731 | Antibody-mediated Rejection | Phase 2 | ACTIVE NOT_RECRUITING | 33 | Nov 1, 2027 | ||||||
| Efgartigimod PH20 SC Small MoleculesNCT06655155 | Systemic Sclerosis (SSc) | Phase 2 | ACTIVE NOT_RECRUITING | 87 | Oct 1, 2027 | ||||||
| Efgartigimod BiologicsMarketedNCT07284420 | AChR-Ab Seropositive Generalized Myasthenia Gravis | Approved | RECRUITING | 70 | Mar 7, 2028 | ||||||
| Cusatuzumab BiologicsNCT04150887 | Leukemia, Myeloid, Acute | Phase 2 | ACTIVE NOT_RECRUITING | 170 | May 15, 2027 | ||||||
| ARGX-119 BiologicsNCT07287982 | Spinal Muscular Atrophy (SMA) | Phase 2 | RECRUITING | 60 | May 28, 2029 | ||||||
| ARGX-119 BiologicsNCT06436742 | Congenital Myasthenic Syndrome | Phase 1 | ACTIVE NOT_RECRUITING | 15 | Jan 24, 2028 | ||||||
| ARGX-124 BiologicsNCT07377396 | Undisclosed | Phase 1 | RECRUITING | 104 | Dec 31, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ARGX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| efgartigimod BreakthroughPriority | autoimmune myositis | Phase 3 | 2026-11-07 | primary result: 15.4-point improvement in Total Improvement Score at Week 52 compared to placebo; improvement IMNM: 14.8-point greater improvement in mean TIS versus placebo at Week 52; TIS 40: 22.0 percentage-point difference in achieving TIS ≥ 40 at Week 52; MMT 8: 5.4 points greater improvement in Manual Muscle Testing-8 versus placebo; CK reduction: 43.5 percentage-point greater reduction in CK levels from baseline versus placebo; CK grade: 0.9-grade greater reduction in CK gradeRead More | argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune MyositisRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in ARGX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 8.3 % (15.3 %) | 927.77 M | 1.00 M |
Ownership Trends
ARGX Short Interest
Shares sold short, counted twice a month.
2.25%
Short % of Float
of tradable shares sold short
1.4M
Shares Sold Short
+4.3% vs prior count
3.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
413.0K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ARGX ranks across every disease it competes in
Competitive Position is a premium feature
See how ARGX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialARGX News
ARGXargenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
argenx announced its acquisition of Unnatural Products, Inc. for up to $1.15 billion. This deal enhances argenx's capabilities in immunology, particularly in developing oral and long-acting medicines. UNP will maintain its operations in Santa Cruz, California, preserving its culture and team. The acquisition is expected to close by year-end, pending customary conditions.
Read more →ARGXUnnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
argenx announced its acquisition of Unnatural Products, Inc. for up to $1.15 billion, including $550 million upfront. This acquisition aims to enhance argenx's capabilities in developing oral macrocyclic peptides. UNP will continue operations in Santa Cruz, contributing to argenx's innovation in immunology. The deal is expected to close by year-end, pending customary conditions.
Read more →ARGXargenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
argenx presented data from the Phase 3 ALKIVIA study at ACR Convergence 2026, showing that efgartigimod significantly improved outcomes in patients with autoimmune myositis. The study met its primary endpoint, demonstrating a 15.4-point improvement in the Total Improvement Score at Week 52 compared to placebo. Efgartigimod was well tolerated, supporting its potential as the first targeted treatment for immune-mediated necrotizing myopathy.
Read more →ARGXargenx to Present at Upcoming Investor Conferences
argenx announced its participation in two upcoming investor conferences in November. The management team will engage in fireside chats at the Guggenheim 3rd Annual Healthcare Innovation Conference and the Jefferies London Global Healthcare Conference. Live webcasts of these presentations will be available on the company's website.
Read more →ARGXargenx Reports Third Quarter 2026 Financial Results and Provides Business Update
argenx reported strong third quarter 2026 results with $1.7 billion in net sales, a 54% increase year-over-year. The company is on track to submit a supplemental biologics license application for VYVGART in ocular myasthenia gravis by year-end. Upcoming Phase 3 data for empasiprubart in multifocal motor neuropathy is expected in December 2026.
Read more →ARGXargenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
argenx announced positive results from the Phase 3 ALKIVIA study, demonstrating that efgartigimod significantly improves symptoms in patients with autoimmune myositis, particularly IMNM and DM. The results will be presented as a late-breaking oral presentation at ACR Convergence 2026. The study achieved its primary endpoint, showing a substantial improvement in the Total Improvement Score compared to placebo.
Read more →ARGXargenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
argenx has announced a conference call scheduled for October 22, 2026, to discuss its third quarter financial results and provide a business update. The call will be accessible via a live webcast and phone dial-in options. The company emphasizes its commitment to immunology innovation and the development of treatments for underserved diseases.
Read more →ARGX▼ -11.8%on this news
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
argenx announced positive topline results from a Phase 2 study of FB102, a CD122 inhibitor, in adults with celiac disease. The study met its primary endpoint, showing a significant change in the villus height-to-crypt depth ratio compared to placebo. The safety profile was consistent with prior studies, and argenx plans to advance FB102 into Phase 3 development.
Read more →ARGX▼ -11.8%on this news
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
argenx SE has announced the discontinuation of its Phase 3 UNITY study of efgartigimod SC in Sjögren's disease, following a recommendation from an Independent Data Monitoring Committee. The study was halted for futility after an interim analysis indicated it could not meet its primary endpoint. Despite consistent safety profiles, this outcome is a setback for patients awaiting effective treatments.
Read more →ARGXargenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
argenx presented new data at the AANEM and MGFA sessions, highlighting VYVGART's effectiveness in treating myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The data showed significant improvements in ocular MG and sustained efficacy in patients without detectable anti-AChR antibodies. Additionally, real-world evidence indicated that earlier treatment with VYVGART leads to better patient outcomes.
Read more →ARGXargenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
argenx SE announced the results of its Extraordinary General Meeting, appointing Thomas M. Brakel and Khurem Farooq as non-executive directors. The company emphasizes its commitment to scientific innovation and enhancing shareholder value. The appointments are seen as a strategic move to strengthen the Board as argenx aims for long-term growth and impact in immunology.
Read more →ARGX▲ +16%on this news
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
argenx announced positive topline results from the Phase 3 ALKIVIA trial of efgartigimod in patients with autoimmune myositis. The study met its primary endpoint, demonstrating a significant improvement in the Total Improvement Score at 52 weeks. Efgartigimod showed consistent benefits across both IMNM and DM subtypes, marking a significant advancement in treatment options for these patients.
Read more →ARGXargenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
argenx SE has announced an Extraordinary General Meeting of Shareholders scheduled for September 17, 2026, in Amsterdam. The meeting will focus on the proposed appointments of two new non-executive directors to the Board. Shareholders are encouraged to attend in person or vote by proxy, with detailed information available on the company's website.
Read more →ARGXargenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
argenx has announced its acquisition of Forte Biosciences for $77 per share, totaling approximately $2.2 billion. This strategic move aims to enhance argenx's immunology portfolio by adding FB102, a first-in-class anti-CD122 antibody. The acquisition reflects argenx's commitment to expanding its innovative treatment options in immunology.
Read more →ARGX▲ +8.6%on this newsshared move
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
argenx reported strong financial results for the second quarter of 2026, with $1.5 billion in global product net sales, marking a 60% increase year-over-year. The company successfully launched expanded indications for VYVGART and VYVGART Hytrulo, now covering all gMG serotypes. Key registrational study readouts are expected in the second half of 2026, supporting the company's growth strategy.
Read more →ARGXargenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
argenx has announced a conference call scheduled for July 23, 2026, to discuss its half-year financial results and provide a business update for the second quarter. The call will be accessible via a webcast and various international dial-in numbers. The company focuses on developing treatments for severe autoimmune diseases.
Read more →ARGX▼ -5.6%on this news
argenx to Host Autoimmune Myositis R&D Webinar
argenx is hosting a webinar on June 23, 2026, focusing on autoimmune myositis and their advancements in FcRn leadership. The event will feature key opinion leaders from prestigious institutions discussing the latest research and developments. A live webcast will be available, along with supporting materials on their website.
Read more →ARGXargenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
Argenx presented new data on efgartigimod at EULAR 2026, demonstrating its long-term benefits in myositis and Sjogren's disease. The ALKIVIA+ study showed sustained improvements in myositis patients, while the RHO+ study confirmed maintenance of response in Sjogren's disease. Efgartigimod's safety profile remained consistent across various autoimmune conditions.
Read more →ARGXargenx to Host Myositis R&D Webinar on June 23, 2026
argenx announced a webinar titled 'R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis' scheduled for June 23, 2026. This event is part of a mini-series aimed at showcasing the company's research and development strategy. The webinar will feature discussions on myositis, including disease biology and the ALKIVIA clinical program for efgartigimod.
Read more →About argenx SE
BIOPHARMAWATCH ELITE
Trade the next ARGX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime